Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes

Leukemia volume 17, pages 1499–1507 (2003)Cite this article

Abstract

Arsenic trioxide (ATO) has a long history of efficacy as an antileukemic agent. However, with the advent of modern therapy, it had been relegated to a historical footnote. In the 1990s, investigators in China reported that ATO was safe and had dramatic efficacy in patients with acute promyelocytic leukemia (APL). Preclinical investigations indicate that the biological targets of this novel drug extend to a variety of malignancies other than APL and include induction of apoptosis, nonterminal differentiation, and suppression of proliferation and angiogenesis. The myelodysplastic syndromes (MDSs) present a particular therapeutic challenge. Ineffective hematopoiesis predominates in patients with low-grade prognostic scores. The survival of those patients with high-grade disease is compromised by a high risk of leukemia transformation. Although a number of therapeutic options have been investigated, none has emerged as being broadly efficacious and having an acceptable toxicity profile. No drug has yet received approval by the Food and Drug Administration for this indication. Biologic features of MDS, which include accelerated apoptotic potential, limited maturation capacity, and medullary neovascularity, create a strong scientific rationale for the investigation of ATO in MDS. This report describes the history and scientific basis for ATO treatment of hematologic malignancies, enumerates the potential benefits of ATO in MDS, and discusses the direction of ongoing trials of this novel antineoplastic agent.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG . Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87: 743–745.

    Article  CAS  PubMed  Google Scholar 

  2. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427–1434.

    Article  CAS  PubMed  Google Scholar 

  3. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268–276.

    CAS  PubMed  Google Scholar 

  4. Greenberg PL . Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leukemia Res 1998; 22: 1123–1136.

    Article  CAS  Google Scholar 

  5. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103: 176–188.

    Article  CAS  PubMed  Google Scholar 

  6. Mundle SD, Ali A, Cartlidge JD, Reza S, Alvi S, Showel MM et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 1999; 60: 36–47.

    Article  CAS  PubMed  Google Scholar 

  7. Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999; 140: 201–207.

    Article  CAS  PubMed  Google Scholar 

  8. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL . Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88: 4275–4287.

    CAS  PubMed  Google Scholar 

  9. Davis RE, Greenberg PL . Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leukemia Res 1998; 22: 767–777.

    Article  CAS  Google Scholar 

  10. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ . ‘Low-risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998; 103: 1075–1082.

    Article  CAS  PubMed  Google Scholar 

  11. Soignet SL, Maslak P, Wang Z-G, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–1348.

    Article  CAS  PubMed  Google Scholar 

  12. Chen G-Q, Shi X-G, Tang W, Xiong S-M, Zhu J, Cai X et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345–3353.

    CAS  PubMed  Google Scholar 

  13. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124–133.

    Article  CAS  PubMed  Google Scholar 

  14. Perkins C, Kim CN, Fang G, Bhalla KN . Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL . Blood 2000; 95: 1014–1022.

    CAS  PubMed  Google Scholar 

  15. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S . Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893–3903.

    CAS  PubMed  Google Scholar 

  16. Hong SH, Yang Z, Privalsky ML . Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia. Mol Cell Biol 2001; 21: 7172–7182.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wang Z-G, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood 1998; 92: 1497–1504.

    CAS  PubMed  Google Scholar 

  18. Li YM, Broome JD . Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999; 59: 776–780.

    CAS  PubMed  Google Scholar 

  19. Zhu X-H, Shen Y-L, Jing Y-K, Cai X, Jia P-M, Huang 0Y et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772–778.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12: 1383–1391.

    Article  CAS  PubMed  Google Scholar 

  21. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S . Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102–2111.

    CAS  PubMed  Google Scholar 

  22. Huang X-J, Wiernik PH, Klein RS, Gallagher RE . Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 1999; 16: 58–64.

    Article  CAS  PubMed  Google Scholar 

  23. Chen G-Q, Zhu J, Shi X-G, Ni J-H, Zhong H-J, Si G-Y et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052–1061.

    CAS  PubMed  Google Scholar 

  24. Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP et al. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999; 27: 845–852.

    Article  CAS  PubMed  Google Scholar 

  25. Dai J, Weinberg RS, Waxman S, Jing Y . Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268–277.

    CAS  PubMed  Google Scholar 

  26. Yang C-H, Kuo M-L, Chen J-C, Chen Y-C . Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999; 81: 796–799.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY et al. Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase. J Biol Chem 2000; 275: 36062–36066.

    Article  CAS  PubMed  Google Scholar 

  28. Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM et al. Phenylarsine oxide blocks interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 1999; 94: 2844–2853.

    CAS  PubMed  Google Scholar 

  29. Arbabi S, Maier RV . Mitogen-activated protein kinases. Crit Care Med 2002; 30(Suppl. 1): S74–S79.

    Article  CAS  PubMed  Google Scholar 

  30. Davison K, Mann KK, Miller Jr WH . Arsenic trioxide: mechanisms of action. Semin Hematol 2002; 39(Suppl. 1): 3–7.

    Article  CAS  PubMed  Google Scholar 

  31. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996; 63: 265–278.

    Article  CAS  PubMed  Google Scholar 

  32. Tennant GB, Walsh V, Truran LN, Edwards P, Mills KI, Burnett AK . Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br J Haematol 2000; 111: 853–862.

    CAS  PubMed  Google Scholar 

  33. Tenen DG, Hromas R, Licht JD, Zhang DE . Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90: 489–519.

    CAS  PubMed  Google Scholar 

  34. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60: 3065–3071.

    CAS  PubMed  Google Scholar 

  35. Park J-W, Choi Y-J, Jang MA, Baek S-H, Lim JH, Passaniti T et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and Bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun 2001; 286: 726–734.

    Article  CAS  PubMed  Google Scholar 

  36. Giles FJ . The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Huntingt) 2002; 16(Suppl. 4): 23–29.

    Google Scholar 

  37. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH . Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999; 59: 6033–6037.

    CAS  PubMed  Google Scholar 

  38. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell Jr RP et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525–1530.

    CAS  PubMed  Google Scholar 

  39. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976; 33: 451–458.

    Article  CAS  PubMed  Google Scholar 

  40. Kwong YL, Todd D . Delicious poison: arsenic trioxide for the treatment of leukemia (letter). Blood 1997; 89: 3487–3488.

    CAS  PubMed  Google Scholar 

  41. Forkner CE, Scott TFM . Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931; 97: 3–5.

    Article  Google Scholar 

  42. Zhang P, Wang SY, Hu XH . Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996; 17: 58–62.

    Google Scholar 

  43. Shen Z-X, Chen G-Q, Ni J-H, Li X-S, Xiong S-M, Qiu Q-Y et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360.

    CAS  PubMed  Google Scholar 

  44. Niu C, Yan H, Yu T, Sun H-P, Liu J-X, Li X-S et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324.

    CAS  PubMed  Google Scholar 

  45. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860.

    Article  CAS  PubMed  Google Scholar 

  46. Dombret H, Fenaux P, Soignet SL, Tallman MS . Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39(Suppl. 2): 8–13.

    Article  CAS  PubMed  Google Scholar 

  47. Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 3136–3143.

    Article  CAS  PubMed  Google Scholar 

  48. Soignet S, Bienvenu BJ, Vongphrachanh P, Garzone P, Cheung N-K, Calleja E et al. A clinical and pharmacologic study of arsenic trioxide (ATO). Clin Cancer Res (in press).

  49. Brunnig R, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW et al. Myelodysplastic syndromes: introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001; pp 63–73.

    Google Scholar 

  50. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting. Airlie House, Warrenton, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.

    Article  CAS  PubMed  Google Scholar 

  51. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395–408.

    CAS  PubMed  Google Scholar 

  52. Gallagher A, Darley RL, Padua R . The molecular basis of myelodysplastic syndromes. Haematologica 1997; 82: 191–204.

    CAS  PubMed  Google Scholar 

  53. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840–849.

    Article  CAS  PubMed  Google Scholar 

  54. Greenberg PL, Sanz GF, Sanz MA . Prognostic scoring systems for risk assessment in myelodysplastic syndromes. Forum (Genova) 1999; 9: 17–31.

    CAS  Google Scholar 

  55. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  56. Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066–3076.

    CAS  PubMed  Google Scholar 

  57. Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990; 76: 36–43.

    CAS  PubMed  Google Scholar 

  58. Willemze R, van der LN, Zwierzina H, Suciu S, Solbu G, Gerhartz H et al. A randomized phase-I/II multicenter study of recombinant human granulocyte–macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. Ann Hematol 1992; 64: 173–180.

    Article  CAS  PubMed  Google Scholar 

  59. Hellstrom-Lindberg E . Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67–71.

    Article  CAS  PubMed  Google Scholar 

  60. Kuter DJ . Future directions with platelet growth factors. Semin Hematol 2000; 37(Suppl. 4): 41–49.

    Article  CAS  PubMed  Google Scholar 

  61. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M . Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001; 19: 4165–4172.

    Article  CAS  PubMed  Google Scholar 

  62. Ganser A, Seipelt G, Lindemann A, Ottmann OG, Falk S, Eder M et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990; 76: 455–462.

    CAS  PubMed  Google Scholar 

  63. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90: 3364–3369.

    CAS  PubMed  Google Scholar 

  64. Visani G, Tosi P, Manfroi S, Ottaviani E, Finelli C, Cenacchi A et al. All-trans retinoic acid in the treatment of myelodysplastic syndromes. Leukemia Lymphoma 1995; 19: 277–280.

    Article  CAS  PubMed  Google Scholar 

  65. Stasi R, Brunetti M, Terzoli E, Amadori S . Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 2002; 99: 1578–1584.

    Article  CAS  PubMed  Google Scholar 

  66. Hofmann WK, Ganser A, Seipelt G, Ottmann OG, Zander C, Geissler G et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol 1999; 78: 125–130.

    Article  CAS  PubMed  Google Scholar 

  67. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429–2440.

    Article  CAS  PubMed  Google Scholar 

  68. Kornblith AB, Herndon II JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002; 20: 2441–2452.

    Article  CAS  PubMed  Google Scholar 

  69. Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 2000; 95: 1580–1587.

    CAS  PubMed  Google Scholar 

  70. Maciejewski JP, Ristiano AM, Sloand EM, Wisch L, Geller N, Barrett JA et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 2002; 117: 119–126.

    Article  CAS  PubMed  Google Scholar 

  71. Rosenfeld C, List A . A hypothesis for the pathogenesis of myelodys-plastic syndromes: implications for new therapies. Leukemia 2000; 14: 2–8.

    Article  CAS  PubMed  Google Scholar 

  72. Rosenfeld C, Bedell C . Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leukemia Res 2002; 26: 721–724.

    Article  CAS  Google Scholar 

  73. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ . Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699–705.

    Article  CAS  PubMed  Google Scholar 

  74. Shimamoto T, Iguchi T, Ando K, Katagiri T, Tauchi T, Ito Y et al. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br J Haematol 2001; 114: 358–361.

    Article  CAS  PubMed  Google Scholar 

  75. Cheson BD . Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leukemia Res 1998; 22(Suppl. 1): S17–S21.

    Article  CAS  Google Scholar 

  76. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1992; 65: 162–168.

    Article  CAS  PubMed  Google Scholar 

  77. Lubbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 2001; 114: 349–357.

    Article  CAS  PubMed  Google Scholar 

  78. Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001; 92: 1999–2015.

    Article  CAS  PubMed  Google Scholar 

  79. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326–2331.

    Article  CAS  PubMed  Google Scholar 

  80. Donelli A, Chiodino C, Panissidi T, Roncaglia R, Torelli G . Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Haematologica 2000; 85: 1002–1003.

    CAS  PubMed  Google Scholar 

  81. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.

    CAS  PubMed  Google Scholar 

  82. List AF . New approaches to the treatment of myelodysplasia. Oncologist 2002; 7(Suppl. 1): 39–49.

    Article  PubMed  Google Scholar 

  83. Anderson KC, Boise LH, Louie R, Waxman S . Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 2002; 8: 12–25.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Arizona Cancer Centre 3945, University of Arizona, Tucson, AZ, USA

    A List

  2. The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    M Beran

  3. Washington University, St. Louis, MO, USA

    J DiPersio

  4. Roswell Park Cancer Institute, Buffalo, NY, USA

    J Slack

  5. Institut Paoli-Calmettes, Marseille, France

    N Vey

  6. Texas Oncology, Dallas, TX, USA

    C S Rosenfeld

  7. Stanford University School of Medicine, Stanford, CA, USA

    P Greenberg

Authors
  1. A List
    View author publications

    Search author on:PubMed Google Scholar

  2. M Beran
    View author publications

    Search author on:PubMed Google Scholar

  3. J DiPersio
    View author publications

    Search author on:PubMed Google Scholar

  4. J Slack
    View author publications

    Search author on:PubMed Google Scholar

  5. N Vey
    View author publications

    Search author on:PubMed Google Scholar

  6. C S Rosenfeld
    View author publications

    Search author on:PubMed Google Scholar

  7. P Greenberg
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

List, A., Beran, M., DiPersio, J. et al. Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 17, 1499–1507 (2003). https://doi.org/10.1038/sj.leu.2403021

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.leu.2403021

Keywords

This article is cited by

Search

Advanced search

Quick links